NCT02033629

Brief Summary

The development of target effect-site controlled concentrations (TCI) of remifentanil have gained increasing acceptance during cardiac surgery as regarding the resulting of hemodynamic stability and early extubation. The use of low-dose opioid technique has been progressively used nowadays because of its ceiling effect to attenuate cardiovascular responses to noxious stimuli. We hypothesize that the use of low target remifentanil effect site concentrations may provide comparable shorter times to tracheal extubation and hemodynamic stability to the use of high remifentanil Ce during target-controlled propofol anesthesia for cardiac surgery.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
75

participants targeted

Target at below P25 for phase_3

Timeline
Completed

Started May 2014

Longer than P75 for phase_3

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

January 9, 2014

Completed
4 days until next milestone

First Posted

Study publicly available on registry

January 13, 2014

Completed
4 months until next milestone

Study Start

First participant enrolled

May 1, 2014

Completed
5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2019

Completed
14 days until next milestone

Study Completion

Last participant's last visit for all outcomes

May 15, 2019

Completed
Last Updated

July 18, 2019

Status Verified

March 1, 2019

Enrollment Period

5 years

First QC Date

January 9, 2014

Last Update Submit

July 16, 2019

Conditions

Keywords

Anesthesiaremifentanilpropofoltarget-controlled infusioncardiac surgery

Outcome Measures

Primary Outcomes (1)

  • time to tracheal extubation

    the times from skin closure to v

    for 4 hours after surgery

Secondary Outcomes (7)

  • times to spontaneous eye opening

    for 5 hours during surgery

  • times from skin closure to return of spontaneous breathing

    for 4 hours after surgery

  • the number of changes in propofol and remifentanil target infusions

    for 6 hours during surgery

  • Number of patients who will need changes in remifentanil effect site concentrations

    For 6 hours during surgery

  • rescue doses of medications

    for 6 hours during surgery

  • +2 more secondary outcomes

Study Arms (3)

Ce 1 ng/ml

ACTIVE COMPARATOR

TCI Remifentanil Ce 1 ng/ml

Drug: Ce 1 ng/ml

Ce 2 ng/ml

ACTIVE COMPARATOR

TCI Remifentanil Ce 2 ng/ml

Drug: Ce 2 ng/ml

Ce 3 ng/ml

PLACEBO COMPARATOR

Remifentanil Ce 3 ng/ml

Drug: Ce 3 ng/ml

Interventions

TCI Remifentanil Ce 1 ng/ml

Ce 1 ng/ml

TCI Remifentanil Ce 2 ng/ml

Ce 2 ng/ml

TCI Remifentanil Ce 3 ng/ml

Ce 3 ng/ml

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Older than 18 years
  • American Society of Anesthesiologists class III and IV
  • eligible for early extubation

You may not qualify if:

  • uncontrolled hypertension
  • ischemic heart disease
  • left ventricular ejection fraction ≤45%
  • mean pulmonary artery pressure ≥50 mm Hg
  • critical aortic stenosis
  • pulmonary diseases
  • hepatic diseases
  • renal diseases
  • neuromuscular diseases
  • neuropsychiatric diseases
  • endocrine diseases
  • body mass index ≥40 kg/m2
  • pregnancy
  • use of antipsychotics
  • use of alcohol
  • +5 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Dammam University

Khobar, Eastern Province, 31952, Saudi Arabia

Location

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 9, 2014

First Posted

January 13, 2014

Study Start

May 1, 2014

Primary Completion

May 1, 2019

Study Completion

May 15, 2019

Last Updated

July 18, 2019

Record last verified: 2019-03

Locations